Comparative Pharmacology
Head-to-head clinical analysis: FLUPHENAZINE HYDROCHLORIDE versus TARACTAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUPHENAZINE HYDROCHLORIDE versus TARACTAN.
FLUPHENAZINE HYDROCHLORIDE vs TARACTAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antipsychotic that blocks postsynaptic dopamine D2 receptors in the mesolimbic system; also exhibits anticholinergic, alpha-adrenergic blocking, and extrapyramidal effects.
Thioxanthene antipsychotic; blocks postsynaptic dopamine D1 and D2 receptors in the mesolimbic system; also has anticholinergic, antihistaminergic, and alpha-adrenergic blocking effects.
2.5-10 mg orally divided every 6-8 hours initially; maintenance 1-5 mg orally daily. For severe psychoses, 2.5-10 mg intramuscularly every 6-8 hours. Maximum oral dose 40 mg/day.
Oral: 25-50 mg three times daily, increased as needed to 400-600 mg/day. IM: 12.5-25 mg every 6-8 hours.
None Documented
None Documented
Terminal elimination half-life 14-24 hours after oral administration; may be longer (up to 48 hours) with chronic use due to accumulation in deep tissues. Clinically, steady state is achieved in 4-7 days.
Terminal elimination half-life is approximately 20-40 hours (mean 30 hours). Steady-state reached in 5-7 days.
Primarily renal (approximately 50-60% as metabolites, <1% unchanged); fecal (30-40% via biliary elimination); small amount excreted in breast milk.
Primarily hepatic metabolism; <1% excreted unchanged in urine. Metabolites eliminated renally (30%) and fecally (70%).
Category A/B
Category C
Typical Antipsychotic
Typical Antipsychotic